A Delaware federal judge on Wednesday ruled that Actavis Laboratories’ generic version of Zohydro ER infringed on two patents for the powerful opioid, held by a Pernix Therapeutics Holdings Inc. subsidiary.
In a 29-page memorandum, U.S. District Judge Gregory M. Sleet of the District of Delaware said that while the generics did not literally infringe on the patents, they performed essentially the same function as Zohydro, which releases hydrocodone over long periods of time to treat severe pain.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
